Addressing Standards of Care in Resource-Limited Settings

被引:6
作者
Dawson, Liza [1 ]
Klingman, Karin L. [1 ]
Marrazzo, Jeanne [2 ]
机构
[1] NIAID, Div AIDS, NIH, Bethesda, MD 20817 USA
[2] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA
关键词
standard of care; treatment guidelines; quality of care; HIV/AIDS; antiretroviral therapy; prevention; HIV PREVENTION TRIALS; DOSE NEVIRAPINE; TRANSMISSION; EXPERIENCES; CHILDREN; WOMEN;
D O I
10.1097/QAI.0000000000000033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The choice between "best-known" standards of care (SOC) or "best available" standards as the control arm in a clinical trial is a fundamental dilemma in clinical research in resource-limited settings (RLS). When the health system is delivering less than an optimal level of care, using highest standard of care in a clinical trial may produce results that cannot be implemented or sustained locally. On the other hand, using interventions that are more feasible in the local setting may involve suboptimal care, and clinical outcomes may be affected. The need for improved standards in health systems in RLS, and the difficulty in securing them, has led many researchers advocate for policy changes at the national or international level to improve clinical care more systemically. SOC decisions in a clinical trial affect the level of benefit provided to study participants and the policy implications of the trial findings. SOC choices should provide high-quality care to help advance the health care system in host countries participating in the trial, but balancing the scientific and ethical objectives of SOC choices is difficult, and there is no single formula for selecting the appropriate SOC. Despite the challenges, well-designed and conducted clinical trials can and should make significant contributions to health systems in RLS.
引用
收藏
页码:S10 / S14
页数:5
相关论文
共 21 条
[1]  
[Anonymous], WHAT DOES IT MEAN MI
[2]  
[Anonymous], GUID US ANT AG HIV 1
[3]  
[Anonymous], CONS GUID US ANT VIR
[4]  
[Anonymous], AM J BIOETH
[5]  
[Anonymous], AM J BIOETH
[6]   BENEFITS TO RESEARCH SUBJECTS IN INTERNATIONAL TRIALS: DO THEY REDUCE EXPLOITATION OR INCREASE UNDUE INDUCEMENT? [J].
Ballantyne, Angela .
DEVELOPING WORLD BIOETHICS, 2008, 8 (03) :178-191
[7]  
Bedri A, 2008, LANCET, V372, P300, DOI 10.1016/S0140-6736(08)61114-9
[8]  
Blanchard-Horan Christina, 2012, Appl Clin Trials, V21, P34
[9]   Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings [J].
Campbell, Thomas B. ;
Smeaton, Laura M. ;
Kumarasamy, N. ;
Flanigan, Timothy ;
Klingman, Karin L. ;
Firnhaber, Cynthia ;
Grinsztejn, Beatriz ;
Hosseinipour, Mina C. ;
Kumwenda, Johnstone ;
Lalloo, Umesh ;
Riviere, Cynthia ;
Sanchez, Jorge ;
Melo, Marineide ;
Supparatpinyo, Khuanchai ;
Tripathy, Srikanth ;
Martinez, Ana I. ;
Nair, Apsara ;
Walawander, Ann ;
Moran, Laura ;
Chen, Yun ;
Snowden, Wendy ;
Rooney, James F. ;
Uy, Jonathan ;
Schooley, Robert T. ;
De Gruttola, Victor ;
Hakim, James Gita .
PLOS MEDICINE, 2012, 9 (08)
[10]   Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial [J].
Coovadia, Hoosen M. ;
Brown, Elizabeth R. ;
Fowler, Mary Glenn ;
Chipato, Tsungai ;
Moodley, Dhayendre ;
Manji, Karim ;
Musoke, Philippa ;
Stranix-Chibanda, Lynda ;
Chetty, Vani ;
Fawzi, Wafaie ;
Nakabiito, Clemensia ;
Msweli, Lindiwe ;
Kisenge, Roderick ;
Guay, Laura ;
Mwatha, Anthony ;
Lynn, Diana J. ;
Eshleman, Susan H. ;
Richardson, Paul ;
George, Kathleen ;
Andrew, Philip ;
Mofenson, Lynne M. ;
Zwerski, Sheryl ;
Maldonado, Yvonne .
LANCET, 2012, 379 (9812) :221-228